Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

ALPHARETTA, Ga. , Oct. 27, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2025 on Wed.

LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Semler Scientific, Inc. (“Semler” or “the Company”) (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2021 and April 15, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before October 29, 2025.

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of WPP plc (NYSE: WPP)? Did you purchase your shares between February 27, 2025 and July 8, 2025, inclusive?

Daqo New Energy Corp. (NYSE:DQ ) Q3 2025 Earnings Call October 27, 2025 8:00 AM EDT Company Participants Jessie Zhao Anita Zhu - Investor Relations Director Ming Yang - Chief Financial Officer Conference Call Participants Philip Shen - ROTH Capital Partners, LLC, Research Division Alan Lau - Jefferies LLC, Research Division Mengwen Wang - Goldman Sachs Group, Inc., Research Division Gordon Johnson - GLJ Research, LLC Presentation Operator Hello, and welcome to the Daqo New Energy Third Quarter 2025 Results Conference Call. [Operator Instructions] Please note this event is being recorded.

HSBC is set to post Q3 results, with earnings and revenues expected to dip even as investment banking and trading stay strong.

LHX is set to post Q3 results, with growth in key segments but margin pressures likely weighing on earnings.

TWLO's Q3 results are likely to reflect the benefits of AI-driven upgrades across its product suites and strong digital adoption.

DTE's Q3 results may reflect gains from grid upgrades and stronger electric sales, partly offset by higher operating costs.

SHEL eyes higher Q3 output and stronger LNG trading gains, though a Brazil field adjustment may weigh on results.

GNRC's third-quarter results may show modest sales gains, driven by strong energy tech demand but tempered by muted home generator sales.

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Fluor Corporation (NYSE: FLR)? Did you purchase your shares between February 18, 2025 and July 31, 2025, inclusive?

VALENCIA, Calif. , Oct. 27, 2025 /PRNewswire/ -- Cunard's flagship Queen Mary 2 will take center stage in New York Harbor on July 4, 2026, as part of Sail4th 250, the official event marking 250 years since American Independence.

Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months. The shares are currently priced around $15, which is more than 65% lower than their highs in 2023, as investors contend with legal uncertainties, management changes, and slowing sales growth.

MILWAUKEE , Oct. 27, 2025 /PRNewswire/ -- The Ademi Firm is investigating Essential (NYSE: WTRG) for possible breaches of fiduciary duty and other violations of law in its transaction with American Water Works Company, Inc. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

YPF Sociedad Anónima is rated Hold, with shares seen as fairly valued after a post-election rally and improved geopolitical backdrop. YPF's Q2 results were mixed, with flat revenue, negative free cash flow, and rising net debt amid a challenging oil market and Argentina's uncertainties. Valuation is updated: P/E multiple raised to 7.5x, but normalized EPS forecast cut to $5, resulting in a $37.50 fair value estimate.

Novartis (NYSE: NVS) revealed plans of acquiring Avidity Biosciences Inc (NASDAQ: RNA) in a $12 billion all-cash transaction – valuing each share of the biotech company at $72 on Monday. The announcement sent RNA shares soaring roughly 44% in a single session – indicating investor enthusiasm and confidence in the buyout terms.

FSLR's Q3 results may shine on robust solar demand and Section 45X tax credits, though tariffs and costs could limit gains.

Village Farms' surge reflects its pivot to a pure-play cannabis model, record profitability and a confident $10M share buyback.

Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.